Keros Therapeutics Hits 52-Week Low at $9.69 Amidst Major Decline

Keros Therapeutics, Inc., a microcap company in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 9.69 as of June 11, 2026. This significant decline reflects a challenging year for the company, which has seen its stock price plummet by 79.43% over the past year, contrasting sharply with the S&P 500's performance of 22.78% during the same period. The company's financial metrics reveal a concerning trend, with net sales dropping dramatically by 99.83%. Keros Therapeutics reported a pre-tax profit of USD -23.71 million, marking a decline of 114.96%, and a net profit of USD -23.71 million, down 115.97%. These figures indicate a consistent struggle, as the company has faced five consecutive quarters of negative results. With a market capitalization of USD 433 million, Keros Therapeutics is currently trading at a price-to-earnings ratio of 5.00 and a price-to-book ratio of 1.43. The company has not declared any dividends, and its debt-to-equity ratio stands at -0.94, further highlighting its financial challenges.